IPO - ARTELO BIOSCIENCES, INC.

Form Type: S-1

Filing Date: 2025-07-11

Corporate Action: Ipo

Type: New

Accession Number: 000164033425001190

Filing Summary: Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics that target lipid-signaling modulation pathways, particularly the endocannabinoid system (ECS). The company is advancing a dual cannabinoid agonist, ART27.13, intended for cancer-related anorexia, and a FABP5 inhibitor, ART26.12, aimed at chemotherapy-induced peripheral neuropathy and various cancers. Artelo has received FDA clearance for clinical trials of ART26.12 and has reported favorable results from its initial studies. The prospectus contains details on the registration of 920,092 shares of common stock for resale by several selling securityholders, following a private placement that closed in June 2025. The combination purchase price for the securities involved in the registration includes associated warrants at specified exercise prices. No proceeds from the sale will go to Artelo, but it stands to benefit from cash received from any exercised warrants. The company's approach highlights its commitment to developing innovative therapeutics for unmet healthcare needs, with a focus on lipid-signaling pathways and cannabinoid therapies.